Home › NDC Lookup › RxCUI directory › RxCUI 597747

Sorafenib 200 MG Oral Tablet — RxCUI 597747

RxNorm drug concept · Semantic clinical drug
RxCUI 597747 Semantic clinical drug · SCD ● Current RxNorm concept 9 FDA products 15 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI597747
Official nameSorafenib 200 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known assorafenib (as sorafenib tosylate) 200 MG Oral Tablet
FDA products mapped9
Package NDCs mapped15
Reported Medicaid activity (SDUD)288 prescriptions · 5 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Sorafenib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Sorafenib — sold as the brand Nexavar or as a generic — is approved for three specific cancers: liver cancer that can't be surgically removed (hepatocellular carcinoma), advanced k...
  • What cancers does sorafenib actually treat?
  • Yes — it really does. You should take sorafenib on an empty stomach, at least 1 hour before eating or 2 hours after a meal. A high-fat meal can reduce how much of the medicine your...
  • Does it matter if I take sorafenib with food?
📖 Read our full Sorafenib guide →

🕸️ Concept Web — How Sorafenib 200 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Sorafenib 200 MG Oral Tablet RxCUI 597747

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Sorafenib 495881
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Nexavar 619985
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Sorafenib Oral Tablet 597746
    • Sorafenib Oral Product 1159691
    • Sorafenib Pill 1159692
    • Sorafenib Oral Tablet [Nexavar] 615978
    • Nexavar Oral Product 1182862
    • Nexavar Pill 1182863
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Sorafenib 200 MG SCDC · 597745
  • Sorafenib Oral Tablet SCDF · 597746
  • Sorafenib Oral Product SCDG · 1159691
  • Sorafenib Pill SCDG · 1159692

Brand-Name Concepts

  • Sorafenib 200 MG Oral Tablet [Nexavar] SBD · 615979
  • Sorafenib 200 MG [Nexavar] SBDC · 615977
  • Sorafenib Oral Tablet [Nexavar] SBDF · 615978
  • Nexavar Oral Product SBDG · 1182862
  • Nexavar Pill SBDG · 1182863
  • Nexavar BN · 619985

📦 FDA Products & Package NDCs

9 products · 15 package NDCs
15 package NDCs map to RxCUI 597747 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00378-1201-78 120 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0378-1201-78) Sorafenib Tosylate Mylan Pharmaceuticals Inc. 2022-06-01
00480-5425-89 120 TABLET, FILM COATED in 1 BOTTLE (0480-5425-89) Sorafenib Teva Pharmaceuticals, Inc. 2023-01-03
13668-0682-12 120 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (13668-682-12) Sorafenib Torrent Pharmaceuticals Limited 2023-04-12
13668-0682-30 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (13668-682-30) Sorafenib Torrent Pharmaceuticals Limited 2023-04-12
13668-0682-60 60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (13668-682-60) Sorafenib Torrent Pharmaceuticals Limited 2023-04-12
13668-0682-74 10 BLISTER PACK in 1 CARTON (13668-682-74) / 10 TABLET, FIL... Sorafenib Torrent Pharmaceuticals Limited 2023-04-12
24979-0715-04 60 TABLET, FILM COATED in 1 BOTTLE (24979-715-04) sorafenib Upsher-Smith Laboratories, LLC 2022-12-01
24979-0715-44 120 TABLET, FILM COATED in 1 BOTTLE (24979-715-44) sorafenib Upsher-Smith Laboratories, LLC 2022-12-01
43598-0458-04 120 TABLET, FILM COATED in 1 BOTTLE (43598-458-04) sorafenib Dr.Reddys Laboratories Inc 2022-06-08
43598-0458-36 360 TABLET, FILM COATED in 1 BOTTLE (43598-458-36) sorafenib Dr.Reddys Laboratories Inc 2022-06-08
50419-0488-58 120 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (50419-488-58) Nexavar Bayer HealthCare Pharmaceuticals Inc. 2005-12-20
50419-0489-01 120 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (50419-489-01) Nexavar Bayer HealthCare Pharmaceuticals Inc. 2023-10-02
51407-0760-12 120 TABLET, FILM COATED in 1 BOTTLE (51407-760-12) sorafenib Golden State Medical Supply, Inc. 2023-04-14
51990-0201-06 60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (51990-201-06) sorafenib Yabao Pharmaceutical Co., Ltd. Beijing 2022-12-01
51990-0201-12 120 TABLET, FILM COATED in 1 PACKAGE (51990-201-12) sorafenib Yabao Pharmaceutical Co., Ltd. Beijing 2022-12-01
Observed labelers: Torrent Pharmaceuticals Limited (4) · Bayer HealthCare Pharmaceuticals Inc. (2) · Dr.Reddys Laboratories Inc (2) · Upsher-Smith Laboratories, LLC (2) · Yabao Pharmaceutical Co., Ltd. Beijing (2) · Golden State Medical Supply, Inc. (1) · +2 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.